Source comparison
ARA-290 Dosage Guide: Protocol Comparison
Before selecting a dosage protocol, researchers must align the dosing strategy with the biological endpoint, model system, and timeline constraints. The table below compares the most commonly referenced ARA-290 dosing regimens from published clinical trials an
This comparison does not assign a generated winner or score.
- Before selecting a dosage protocol, researchers must align the dosing strategy with the biological endpoint, model system, and timeline constraints. The table below compares the most commonly referenced ARA-290 dosing regimens from published clinical trials and research applications.
- Feinstein Institute Phase 2 (Annals of Neurology 2014)
- 4mg subcutaneous
- 3× per week (M/W/F)
- 28 days (12 doses total)
- Sarcoidosis small fiber neuropathy
- NPS pain score reduced 2.8 points (p < 0.01); corneal nerve fiber density increased 0.8 mm/mm²
- Gold standard protocol. Strongest clinical evidence for neuroprotective efficacy
- Diabetes Care Phase 2 (Type 2 DM neuropathy)
- 2mg subcutaneous
- Daily
- 28 days
- Diabetic peripheral neuropathy
- Modest improvement in vibration perception; pain reduction non-significant
- Lower efficacy than 4mg 3×/week despite higher total dose. Suggests receptor dynamics favor intermittent dosing
- Dose-escalation safety study
- 8mg subcutaneous
- Single dose or 3× per week
- Variable (up to 12 weeks)
- Safety/tolerability assessment
- No serious adverse events; no hematological changes
- Establishes upper dosing boundary. Doses above 8mg add exposure without additional receptor activation
- Preclinical neuroprotection model (rodent)
- 1mg subcutaneous
- 14 days
- Chemotherapy-induced peripheral neuropathy
- Preserved nerve conduction velocity; reduced mechanical allodynia
- Effective at lower dose in acute injury models. Human translation typically requires 2–4× dose adjustment
- The comparison makes clear that the 4mg three-times-weekly protocol balances efficacy, total exposure, and convenience. It's the dosing strategy most likely to replicate published outcomes in similar applications.